New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
06:04 EDTIMUC, NBSImmunoCellular expands relationship with NeoStem subsidiary
ImmunoCellular Therapeutics (IMUC) announced the expansion of its relationship with Progenitor Cell Therapy, or PCT, a subsidiary of NeoStem, (NBS), for current good manufacturing practices services for ImmunoCellular's dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, in a phase I clinical trial for recurrent glioblastoma multiforme pursuant to a Services Agreement between the companies. PCT also manufactured phase II clinical supplies of ICT-107, a dendritic cell-based vaccine targeting six tumor-associated antigens for newly diagnosed GBM. Under this newly executed Services Agreement, PCT will manufacture clinical supplies of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer antigens, using process improvements PCT will develop that can be applied to the manufacture of all ImmunoCellular's current vaccine product candidates, ICT-107, ICT-121 and ICT- 140.
News For IMUC;NBS From The Last 14 Days
Check below for free stories on IMUC;NBS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:19 EDTIMUCLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 14, 2014
07:06 EDTNBSNeoStem announces definitive agreement to acquire California Stem Cell
Subscribe for More Information
07:04 EDTNBSNeoStem announces definitive agreement to acquire California Stem Cell
Subscribe for More Information
06:59 EDTNBSNeoStem trading halted, pending news
06:02 EDTNBSNeoStem to host corporate conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use